STOCKHOLM: Swedish Orphan Biovitrum, which specialises in selling medicine for rare diseases, said it has received a preliminary proposal for a bid on the firm, the latest company to be sucked into a whirl of deal-making in the healthcare sector.
The confirmation followed a Bloomberg report, which said the company had held on and off talks with potential buyers since last year and was reviewing a preliminary takeover offer.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!